MTOR and meningioma: Moreover, another mTOR inhibitor drug, Vistusertib (AZD-2014), currently in phase II clinical trial for meningioma, was reported to have a positive impact by mTORC1/2 inhibition of the resistance to MAPK pathway inhibitors in melanomas with high oxidative phosphorylation [44, 45].